Anavex Life Sciences Corp (AVXL)

[falconer66a]

Is Dr. Klamer risking his professional career?

https://www.discoveryontarget.com/CNS-Neurodegenerative-Targets

It is interesting to note that at this conference (26 September, in Boston) Daniel Klamer, PhD, MBA, Vice President, Business Development & Scientific Strategy, of Anavex Life Sciences Corp, will physically appear and present his presentation’s information. Among many other things, the announcement noted that Dr. Klamer will contend that “ANAVEX 2-73 is an orally available drug candidate that restores cellular homeostasis by activating the sigma-1 receptor.”

Just who, do you suppose, will be in Dr. Klamer’s audience at this medical research professionals conference? Stock message board hacks off the street? Or medical professionals who conduct medical research? Might anyone in the audience challenge Dr. Klamer’s claims regarding blarcamesine (Anavex 2-73)?

It would seem that if, as many here contend, that Anavex doesn’t actually have substantiating safety and efficacy data from their clinical trials Dr. Klamer will have to offer some embarrassing equivocations on the topic.

Or — make your choice — Dr. Klamer knows full well that Anavex has the substantiating data, which will be revealed some time in the future. Although not likely to be revealed by Dr. Klamer at this Boston conference, he can confidently state that when the time is right, the clinical data from blarcamesine trials will substantiate all that he will be claiming at the conference, and will allow FDA approval.

Or, he will just have to make up answers to questions about blarcamesine and hope that all of the contentious issues fade quietly from discussion.

If you were this Dr. Klamer, would you put yourself before a roomful of medical research professionals knowing that the points in your presentation about blarcamesine simply lack evidence-based substantiation? Professionally pretty risky. Actually, career-ending.

What, then, might you suppose Dr. Klamer actually knows about blarcamesine? Is he risking his professional career by making this appearance and presentation? Or....